6NMV

Non-Blocking Fab 218 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1

Summary for 6NMV

• Entry DOI: 10.2210/pdb6nmv/pdb
• Related: 6NMR 6NMS 6NMT 6NMU
• Descriptor: Tyrosine-protein phosphatase non-receptor type substrate 1, Fab 218 anti-SIRP-alpha antibody Variable Heavy Chain, Fab 218 anti-SIRP-alpha antibody Variable Light Chain, ... (4 entities in total)
• Functional Keywords: sirp-alpha, signal regulatory protein alpha, signal-regulatory protein alpha, tyrosine-protein phosphatase non-receptor type substrate 1, cd47, cluster of differentiation 47, anti-sirp-alpha antibody, blocking anti-sirp-alpha antibody, non-blocking anti-sirp-alpha antibody, kick-off anti-sirp-alpha antibody, anti-sirp-alpha antibody in complex with sirp-alpha, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 3
• Total formula weight: 59513.22

Authors

Wibowo, A.S.,Carter, J.J.,Sim, J. (deposition date: 2019-01-11, release date: 2019-08-07, Last modification date: 2024-10-16)

Primary citation

Sim, J.,Sockolosky, J.T.,Sangalang, E.,Izquierdo, S.,Pedersen, D.,Harriman, W.,Wibowo, A.S.,Carter, J.,Madan, A.,Doyle, L.,Harrabi, O.,Kauder, S.E.,Chen, A.,Kuo, T.C.,Wan, H.,Pons, J.
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRP alpha.
Mabs, 11:1036-1052, 2019

PubMed Abstract: Targeting the CD47-signal-regulatory protein α (SIRPα) pathway represents a novel therapeutic approach to enhance anti-cancer immunity by promoting both innate and adaptive immune responses. Unlike CD47, which is expressed ubiquitously, SIRPα expression is mainly restricted to myeloid cells and neurons. Therefore, compared to CD47-targeted therapies, targeting SIRPα may result in differential safety and efficacy profiles, potentially enabling lower effective doses and improved pharmacokinetics and pharmacodynamics. The development of effective SIRPα antagonists is restricted by polymorphisms within the CD47-binding domain of SIRPα, necessitating pan-allele reactive anti-SIRPα antibodies for therapeutic intervention in diverse patient populations. We immunized wild-type and human antibody transgenic chickens with a multi-allele and multi-species SIRPα regimen in order to discover pan-allelic and pan-mammalian reactive anti-SIRPα antibodies suitable for clinical translation. A total of 200 antibodies were isolated and screened for SIRPα reactivity from which approximately 70 antibodies with diverse SIRPα binding profiles, sequence families, and epitopes were selected for further characterization. A subset of anti-SIRPα antibodies bound to both human SIRPα v1 and v2 alleles with high affinity ranging from low nanomolar to picomolar, potently antagonized the CD47/SIRPα interaction, and potentiated macrophage-mediated antibody-dependent cellular phagocytosis . X-ray crystal structures of five anti-SIRPα antigen-binding fragments, each with unique epitopes, in complex with SIRPα (PDB codes 6NMV, 6NMU, 6NMT, 6NMS, and 6NMR) are reported. Furthermore, some of the anti-SIRPα antibodies cross-react with cynomolgus SIRPα and various mouse SIRPα alleles (BALB/c, NOD, BL/6), which can facilitate preclinical to clinical development. These properties provide an attractive rationale to advance the development of these anti-SIRPα antibodies as a novel therapy for advanced malignancies. : ADCC: antibody-dependent cellular cytotoxicity; ADCP: antibody-dependent cellular phagocytosis; CFSE: carboxyfluorescein succinimidyl ester; Fab: fragment antigen binding; Fc: fragment crystallizable; FcγR: Fcγ receptor; Ig: immunoglobulin; IND: investigational new drug; MDM⊘: monocyte-derived macrophage; NOD: non-obese diabetic; scFv: single chain fragment variable; SCID: severe combined immunodeficiency; SIRP: signal-regulatory protein.

PubMed: 31257988
DOI: 10.1080/19420862.2019.1624123

Experimental method

X-RAY DIFFRACTION (2.61 Å)